Home » OXiGENE Earns Orphan Drug Designation for Pancreatic Cancer Treatment
OXiGENE Earns Orphan Drug Designation for Pancreatic Cancer Treatment
The European Commission has granted orphan drug designation to fosbretabulin for the treatment of gastro-entero-pancreatic neuroendocrine tumors.
The vascular-disrupting agent nabbed orphan drug status from the FDA earlier this year for the same indication.
Upcoming Events
-
07May
-
14May
-
30May